239 related articles for article (PubMed ID: 33991528)
41. Clinicopathological Correlates of PIT1 and SF1-Multilineage Pituitary Neuroendocrine Tumors and the Diagnostic Utility of NKX2.2 Immunohistochemistry in Pituitary Pathology.
Doğukan FM; Karatay H; Yüzkan S; Burhan Ş; Erkan B; Yılmaz-Özgüven B
Arch Pathol Lab Med; 2024 Apr; ():. PubMed ID: 38649148
[TBL] [Abstract][Full Text] [Related]
42. [Overview of the New World Health Organization Classification of Pituitary Neuroendocrine Tumors].
Kurosaki M
No Shinkei Geka; 2023 Sep; 51(5):910-916. PubMed ID: 37743343
[TBL] [Abstract][Full Text] [Related]
43. Two Pituitary Neuroendocrine Tumors (PitNETs) with Very High Proliferation and TP53 Mutation - High-Grade PitNET or PitNEC?
Saeger W; Mawrin C; Meinhardt M; Wefers AK; Jacobsen F
Endocr Pathol; 2022 Jun; 33(2):257-262. PubMed ID: 34669159
[TBL] [Abstract][Full Text] [Related]
44. Annotation of pituitary neuroendocrine tumors with genome-wide expression analysis.
Tebani A; Jotanovic J; Hekmati N; Sivertsson Å; Gudjonsson O; Edén Engström B; Wikström J; Uhlèn M; Casar-Borota O; Pontén F
Acta Neuropathol Commun; 2021 Nov; 9(1):181. PubMed ID: 34758873
[TBL] [Abstract][Full Text] [Related]
45. FSH-producing pituitary neuroendocrine tumor as a cause of ovarian hyperstimulation syndrome.
Kitamura T; Nanba K; Doi K; Kishimoto N; Abiko K; Kuwahara R; Moriyoshi K; Inoshita N; Tagami T
Endocrinol Diabetes Metab Case Rep; 2024 Jan; 2024(1):. PubMed ID: 38421932
[TBL] [Abstract][Full Text] [Related]
46. The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph.
Asa SL; Bamberger AM; Cao B; Wong M; Parker KL; Ezzat S
J Clin Endocrinol Metab; 1996 Jun; 81(6):2165-70. PubMed ID: 8964846
[TBL] [Abstract][Full Text] [Related]
47. [Epidemiology, Genetics and Pathogenesis of Pituitary Neuroendocrine Tumors].
Suzuki K; Tahara S
No Shinkei Geka; 2023 Jul; 51(4):593-606. PubMed ID: 37491056
[TBL] [Abstract][Full Text] [Related]
48. Prolactin and Growth Hormone Signaling and Interlink Focused on the Mammosomatotroph Paradigm: A Comprehensive Review of the Literature.
Araujo-Castro M; Marazuela M; Puig-Domingo M; Biagetti B
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762304
[TBL] [Abstract][Full Text] [Related]
49. TGFBR3L is associated with gonadotropin production in non-functioning gonadotroph pituitary neuroendocrine tumours.
Kolnes AJ; Øystese KAB; Sjöstedt E; Olarescu NC; Heck A; Pahnke J; Dahlberg D; Berg-Johnsen J; Ringstad G; Casar-Borota O; Bollerslev J; Jørgensen AP
Pituitary; 2023 Apr; 26(2):227-236. PubMed ID: 36952069
[TBL] [Abstract][Full Text] [Related]
50. Differences in invasiveness and recurrence rate among nonfunctioning pituitary neuroendocrine tumors depending on tumor subtype.
Taguchi A; Kinoshita Y; Amatya VJ; Onishi S; Go Y; Tominaga A; Takeshima Y; Yamasaki F; Horie N
Neurosurg Rev; 2023 Nov; 46(1):317. PubMed ID: 38030890
[TBL] [Abstract][Full Text] [Related]
51. An Update on Pituitary Neuroendocrine Tumors Leading to Acromegaly and Gigantism.
Asa SL; Ezzat S
J Clin Med; 2021 May; 10(11):. PubMed ID: 34067494
[TBL] [Abstract][Full Text] [Related]
52. An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors.
Alshaikh OM; Asa SL; Mete O; Ezzat S
Endocr Pathol; 2019 Jun; 30(2):118-127. PubMed ID: 30706322
[TBL] [Abstract][Full Text] [Related]
53. Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors.
Herrgott GA; Asmaro KP; Wells M; Sabedot TS; Malta TM; Mosella MS; Nelson K; Scarpace L; Barnholtz-Sloan JS; Sloan AE; Selman WR; deCarvalho AC; Poisson LM; Mukherjee A; Robin AM; Lee IY; Snyder J; Walbert T; Rosenblum M; Mikkelsen T; Bhan A; Craig J; Kalkanis S; Rock J; Noushmehr H; Castro AV
Neuro Oncol; 2022 Jul; 24(7):1126-1139. PubMed ID: 35212383
[TBL] [Abstract][Full Text] [Related]
54. Transcriptomic analysis identifies a tumor subtype mRNA classifier for invasive non-functioning pituitary neuroendocrine tumor diagnostics.
Bao X; Wang G; Yu S; Sun J; He L; Zhao H; Ma Y; Wang F; Wang X; Wang R; Yu J
Theranostics; 2021; 11(1):132-146. PubMed ID: 33391466
[No Abstract] [Full Text] [Related]
55. Neuropathology of Pituitary Adenomas and Sellar Lesions.
Kobalka PJ; Huntoon K; Becker AP
Neurosurgery; 2021 Apr; 88(5):900-918. PubMed ID: 33476394
[TBL] [Abstract][Full Text] [Related]
56. Single-cell transcriptomic analysis reveals tumor cell heterogeneity and immune microenvironment features of pituitary neuroendocrine tumors.
Yan N; Xie W; Wang D; Fang Q; Guo J; Chen Y; Li X; Gong L; Wang J; Guo W; Zhang X; Zhang Y; Gu J; Li C
Genome Med; 2024 Jan; 16(1):2. PubMed ID: 38167466
[TBL] [Abstract][Full Text] [Related]
57. Co-occurrence of Pituitary Neuroendocrine Tumors (PitNETs) and Tumors of the Neurohypophysis.
Saeger W; von Schöning J; Flitsch J; Jautzke G; Bergmann M; Hagel C; Knappe UJ
Endocr Pathol; 2021 Dec; 32(4):473-479. PubMed ID: 34129177
[TBL] [Abstract][Full Text] [Related]
58. Progress in the Pathogenesis, Diagnosis, and Treatment of TSH-Secreting Pituitary Neuroendocrine Tumor.
Luo P; Zhang L; Yang L; An Z; Tan H
Front Endocrinol (Lausanne); 2020; 11():580264. PubMed ID: 33329389
[TBL] [Abstract][Full Text] [Related]
59. Risk of Recurrence in Pituitary Neuroendocrine Tumors: A Prospective Study Using a Five-Tiered Classification.
Raverot G; Dantony E; Beauvy J; Vasiljevic A; Mikolasek S; Borson-Chazot F; Jouanneau E; Roy P; Trouillas J
J Clin Endocrinol Metab; 2017 Sep; 102(9):3368-3374. PubMed ID: 28651368
[TBL] [Abstract][Full Text] [Related]
60. Differential expression levels of β-catenin are associated with invasive behavior of both functional and non-functional pituitary neuroendocrine tumor (PitNET).
Taghavi SF; Ghorbani M; Panahi M; Nazem S; Karimi M; Salimi V; Tavakoli-Yaraki M
Mol Biol Rep; 2023 Aug; 50(8):6425-6434. PubMed ID: 37326745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
